Pattern of disease and response to pembrolizumab in recurrent cervical cancer

Pattern of disease and response to pembrolizumab in recurrent cervical cancer

Objective: Since the approval of pembrolizumab for advanced or recurrent PD-L1 positive (CPS > 1%) cervical cancer, the clinical characteristics associated with response have remained undefined. We sought to characterize the clinicopathologic features of patients with advanced cervical cancer at...

Full description

Bibliographic Details
Main Authors: Kathryn M. Miller, Olga T. Filippova, Sara A. Hayes, Nadeem R. Abu-Rustum, Carol Aghajanian, Vance Broach, Lora H. Ellenson, Pier Selenica, Elizabeth L. Jewell, Chrisann Kyi, Yuliya Lakhman, Jennifer J. Mueller, Roisin E. O'Cearbhaill, Kay J. Park, Yukio Sonoda, Dmitriy Zamarin, Britta Weigelt, Mario M. Leitao, Jr, Claire F. Friedman
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Gynecologic Oncology Reports
Subjects:
Immune checkpoint blockade
Cervical cancer
PD-1 resistance
Tumor microenvironment
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578921001351

Internet

http://www.sciencedirect.com/science/article/pii/S2352578921001351

Similar Items